Adoptive transfer of activated macrophages, being both effector cells and antigen-presenting cells, represents a promising approach to immunotherapy of cancer. In order to get activated macrophages with increased antitumor potential, in the present study, murine peritoneal macrophages were transduced with human macrophage colony-stimulating factor (M-CSF) and murine interferon-␥ (IFN␥) by recombinant adenovirus infection. The results demonstrate that M-CSF and IFN␥ gene-modified macrophages exhibited higher expression of MHC-II, B7.1 and ICAM-1, increased antigenpresenting activity and cytotoxicity. It was also shown that they secreted more tumor necrosis factor, interleukin-1 and
Introduction
Immunotherapy with activated macrophages represents a promising novel approach in the treatment of cancer. [1] [2] [3] Tumor antigen-pulsed dendritic cells as tumor vaccine for the treatment of cancer has been intensively studied. [4] [5] [6] [7] Macrophages are not only immunological effector cells but also antigen-presenting cells. Up to now, most of the studies on the antitumor capacity of macrophages are focused on the augmentation of their tumoricidal activity, but their antigen-presenting ability is ignored. If the macrophages were improperly activated or infused into tumor-bearing host with local immunosuppression, they might become inhibitory and lose their antitumor effects. Macrophage colony-stimulating factor (M-CSF) is a key cytokine in the differentiation, growth and function of macrophages. M-CSF was reported to stimulate the release of interleukin 1 (IL-1), interferon (IFN␥) and tumor necrosis factor (TNF) by macrophages, augment antibody-dependent and antibody-independent cytotoxicity of macrophages, and prolong the survival of macrophages. [8] [9] [10] [11] IFN␥ is the most potent activator of macrophages. IFN␥ can up-regulate the expression of MHC and nitric oxide. In vivo experiments showed that in previously initiated murine pulmonary metastatic melanoma, tumor lysate-pulsed, M-CSF and IFN␥ gene-modified macrophages elicited more potent antitumor effects than tumor lysate pulsed M-CSF or IFN␥ gene-modified macrophages. Cytotoxic T lymphocyte (CTL) activity, IFN␥ and tumor-necrosis factor production of the splenocytes increased significantly in mice after intravenous injection of the gene-modified macrophages. M-CSF and IFN␥ gene-modified macrophages may act as activated effector and antigen-presenting cells, thus eliciting a more potent antitumor response. Gene Therapy (2000) 7, 707-713.
other surface molecules on macrophages, increase the cytotoxicity and antigen-presenting activity of macrophages. [12] [13] [14] [15] [16] [17] [18] Cytokine production and adhesion molecule expression on myelomonocytic cells were activated by M-CSF in combination with IFN␥. 19 Tumor lysate-or tumor antigen-pulsed antigen-presenting cells have been proved to be efficient tumor vaccine in the immunotherapy of cancer both in animal models and in human patients. 20 So, in the present study, M-CSF cDNA and IFN␥ cDNA were cotransfected into macrophages via recombinant adenovirus to obtain properly activated macrophages. The results demonstrated that M-CSF and IFN␥ could stimulate macrophages synergistically, and tumor lysate-pulsed, gene-modified macrophages elicited potent antitumor effects in pre-established murine metastatic melanoma.
Results
Secretion of M-CSF and IFN␥ by gene-modified macrophages Freshly isolated macrophages were transfected with AdM-CSF and/or AdIFN␥, and the secretion of M-CSF and IFN␥ in the supernatants was detected by ELISA. The results in Figure 1 showed that the contents of M-CSF and IFN␥ could not be detected in the supernatants of normal macrophages and AdLacZ-infected macro- phages. Four hours after AdM-CSF and AdIFN␥ infection, high levels of M-CSF and IFN␥ could be detected, and they reached the highest levels at 48 h and persisted for 10 days. The results indicated that M-CSF and IFN␥ genes were successfully transduced into macrophages and were expressed with high efficiency.
Increased expression of surface molecules on M-CSF and IFN␥ gene-modified macrophages Flow cytometry was utilized for the determination of MHC-II (Ia b ), co-stimulating molecule B7.1, and ICAM-1 (CD54) expression on the gene-modified peritoneal macrophages. The results in Figure 2 demonstrated that transfection of the macrophages with AdIFN␥ or AdM-CSF/AdIFN␥ increased the expression of MHC-II on macrophages obviously as compared with transfection with AdLacZ or treatment with PBS. When AdM-CSF and AdIFN␥ were combined for the transfection of macrophages, higher level of B7.1 was expressed than that on AdlacZ-, AdM-CSF-, AdIFN␥-infected macrophages, or normal macrophages. Macrophages infected with AdM-CSF alone, AdIFN␥ alone, or AdM-CSF/AdIFN␥ expressed higher levels of ICAM-1 when Increased antigen presentation and cytotoxicity of M-CSF and IFN␥ gene-modified macrophages We wished to know whether M-CSF and IFN␥ genemodified macrophages enhanced antigen-presenting function. The peritoneal macrophages were incubated with OVA antigen and mixed with isolated T cells. The contents of IL-2 in the supernatants of mixed macrophages and T cells were determined to evaluate the antigen-presenting activity of gene-modified macrophages. The results in Figure 3a showed that macrophages infected with AdIFN␥ could markedly increase the production of IL-2 by T cells compared with those infected with AdlacZ, AdM-CSF or normal macrophages (P Ͻ 0.05). Combined infection of macrophages with AdM-CSF and AdIFN␥ stimulated the release of more IL-2 by T cells compared with those infected with AdIFN␥ alone (P Ͻ 0.05). The cytotoxic activity of gene-modified macrophages was also determined and the results in Figure 3b illustrate that the macrophages infected with either AdM-CSF or AdIFN␥ showed higher cytotoxicity than those infected with AdlacZ or normal macrophages (P Ͻ 0.05). Combined infection of macrophages with AdM-CSF and AdIFN␥ further increased the cytotoxicity of macrophages.
These data indicated that infection of macrophages with AdM-CSF/AdIFN␥ could markedly increase the antigen-presenting activity and cytotoxicity of macrophages, and that these macrophages might be important for the induction of antitumor immunity. Enhanced production of IL-1, TNF and NO by M-CSF and IFN␥ transduced macrophages The supernatants of the macrophages were collected for IL-1 and TNF bioassay and for determination of NO contents. The results in Table 1 illustrated that macrophages infected with AdM-CSF and AdIFN␥ produced 25.3 ng/ml of IL-1, but IL-1 contents were below the detect limit in the supernatants of normal macrophages or macrophages infected with AdLacZ, AdM-CSF or AdIFN␥. AdIFN␥ infection, alone or in combination with AdM-CSF, stimulated the production of TNF, but TNF was below the detect limit in normal macrophages, AdLacZ-or AdM-CSF-transfected macrophages. For NO Potent antitumor effects of inoculation with tumor lysatepulsed, M-CSF and IFN␥ gene-modified macrophages C57BL/6 mice were inoculated i.v. with 1 × 10 5 B16F10 melanoma cells and 3 days later the tumor-bearing mice were treated with tumor-lysate pulsed, gene modified macrophages. As shown in Figure 4 , active immunotherapy with macrophage alone or lacZ gene-modified macrophages, either with tumor lysate pulsing or not, elicited inhibitory effects on pulmonary metastasis. The tumor-bearing mice treated with AdM-CSF or AdIFN␥ infected macrophages showed less pulmonary metastases as compared with those mice treated with PBS, macrophages alone, or lacZ gene-modified macrophages (P Ͻ 0.05). Immunotherapy with AdM-CSF/AdIFN␥ modified macrophages reduced the pulmonary metastasis in tumor-bearing mice more significantly than as an injection of other macrophage preparation examined here. Tumor lysate-pulsed macrophages showed more potent therapeutic effects as compared with their counterparts. These data demonstrated that intravenous injection of tumor lysate-pulsed, M-CSF and IFN␥ gene-modified macrophages could elicit potent antitumor effects against metastatic melanoma.
Induction of specific antitumor immunity in tumorbearing mice after treatment with tumor lysate-pulsed, M-CSF and IFN␥ gene-modified macrophages CTL induced from spleen cells taken from the dead tumor-bearing mice were utilized in cytotoxic assays against B16F10 cells by a 4-h 51 Cr release method. As shown in Figure 5 , the lymphocytes from mice injected with tumor lysate-pulsed, M-CSF and IFN␥ gene-modified macrophages showed highest cytotoxic activity against B16F10 cells, but not against syngeneic EL4 cells derived from C57BL/6 mice (data not shown). A much lower level of cytotoxicity was detected in splenocytes isolated from the tumor-bearing mice treated with PBS, macrophages alone, AdlacZ gene-modified macrophages, AdM-CSF or AdIFN␥ gene-modified macrophages (P Ͻ 0.05).
The splenocytes were isolated from tumor-bearing mice after various immunotherapies with antigen-pulsed, gene-modified macrophages. Con A 10 g/ml was added to splenocytes to induce TNF and IFN␥ production. The results in Table 2 demonstrate that significantly higher levels of TNF and IFN␥ were produced by splenocytes derived from tumor-bearing mice treated with M-CSF and IFN␥ gene modified macrophages with or without pulsing with tumor lysates when compared with those produced by splenocytes derived from tumor-bearing mice treated with PBS, AdlacZ transfected macrophages, AdM-CSF or AdIFN␥ transfected macrophages (P Ͻ 0.01). These data suggest that the augmentation of antitumor immunity plays an important role in the antitumor response induced by vaccination with tumor-lysates pulsed, M-CSF and IFN␥-gene modified macrophages.
Discussion
In the last decade, immunotherapy has emerged as a treatment modality capable of mediating the regression of cancer. [21] [22] [23] Ex vivo expanded and activated autologous macrophages were re-infused into patients locally or systemically for adoptive immunotherapy of cancer. 3 Within the host defense system against the development and spread of malignant tumors, macrophages are considered to be on the first line of defense. In vivo activation of macrophages can be achieved and can induce destruction of neoplastic cells, which do not develop resistance to macrophage cytotoxicity. This is in contrast with chemotherapeutic and radiation treatments which often lead to the development of resistance or cause mutations in genes critical to enhancing apoptosis. Macrophages can release proteins inducing apoptosis or molecules which render tumor cells sensitive to apoptosis. However, antitumor effects of macrophages in the host were injured for solid tumors growing in animals or humans which could induce suppressive cytokines such as transforming growth factor-␤. 24 Inappropriately activated macrophages were shown to cause abnormal T cell receptor complex formation in tumor-bearing conditions, resulting in immunosuppression of T cell responses. 25 In this study, to activate macrophages efficiently, M-CSF gene and IFN␥ gene were introduced into macrophages and the gene-modified macrophages showed more potent antitumor effects. The antitumoral activity of macrophages was suggested 20 years ago by Dullens and Den Otter 26 who observed that transfer of immune macrophage could confer antitumor resistance to mice. Clinical trials based on activated macrophages as adoptive immunotherapy are currently ongoing. 27, 28 Continued stimulating signals to macrophages after infusion in vivo might be of great importance to the prolonged antitumor effects, and gene transfection might be a promising approach to maintain the production of such stimulating factors to macrophage. Dorsch et al 29 have shown that M-CSF gene transfected tumor could induce macrophage infiltration but not tumor suppression, suggesting that infiltrated macrophages were not activated because there was no activating signal for macrophages (only with the role of M-CSF), and unactivated macrophages could not elicit cytotoxicity and antigenpresenting ability, so were unable to suppress the tumor. In the present study, the two cytokines chosen are important for the differentiation and activation of macrophages. M-CSF increases survival, growth and differentiation of macrophages, and IFN␥ is a macrophage-activating factor. We hope that macrophages could be activated by IFN␥ and their survival time could be prolonged by M-CSF. In the present study, peritoneal macrophages were transfected with M-CSF and IFN␥ gene, and the gene-modified macrophages showed higher expression of MHC-II, B7.1 and ICAM-1 molecules, increased antigen presenting activity and cytotoxicity, and augmented secretion of TNF, IL-1 and NO. In vivo experiments showed that in previously initiated metastatic melanoma, tumor lysate-pulsed, M-CSF and IFN␥ gene-modified macrophages elicited potent antitumor effects. CTL activity, and cytokine production by splenocytes increased significantly in mice after treatment with tumor lysate-pulsed, M-CSF and IFN␥ gene-modified macrophages.
Three mechanisms might have countributed to the increased antitumor efficacy of macrophages after M-CSF and IFN␥ gene modification. Firstly, the gene-modified macrophages could directly kill tumor cells through increased production of mediators such as IL-1, TNF and NO, these mediators could inhibit the DNA synthesis, and possibly induce apoptosis in tumor cells. Secondly, after gene modification, the macrophages express more MHC-II and co-stimulating molecules, thus increasing their antigen presenting activity and stimulating tumorspecific antitumor immunity of the host when pulsed with tumor lysates. Thirdly, the IL-1, M-CSF, and IFN␥ produced by gene-modified macrophages might directly activate non-specific effector cells such as natural killer cells and reverse the local immunosuppression in the tumor microenvironment. These data suggested that M-CSF and IFN␥ gene-modified macrophages might act as potentially activated effector cells and antigen-presenting cells, thus eliciting an enhanced antitumor responses. We speculate that cytokine gene modification of macrophages might be a potentially useful approach to the gene therapy of cancer.
Materials and methods
Cell lines and mice B16F10, a subclone of B16 melanoma cell line derived from C57BL/6 mice, were maintained in RPMI-1640 medium supplemented with penicillin 100 U/ml, streptomycin 100 g/ml, 2-mercaptoethanol 50 mmol/l and 10% fetal calf serum (FCS). L1210 and L929 cell line were maintained in RPMI-1640 medium with 10% FCS. All the media were purchased from Sigma, St Louis, MO, USA, and FCS from Gibco, Grand Island, NY, USA.
Male or female C57BL/6 mice, 6-8 weeks of age, purchased from Joint Ventures Sipper BK Experimental Animal Co, Shanghai, China, were housed for at least 1 week in a specific pathogen-free state before their use in any experiment.
Preparation of recombinant adenoviruses
Three replication-defective recombinant adenoviruses, AdlacZ (harboring ␤-galactosidase gene), AdM-CSF (harboring human M-CSF gene), and AdIFN-␥ (harboring murine IFN␥ gene), were constructed from human adenovirus serotype 5 using homologous recombination. 30, 31 The expression of these genes was driven by CAG promoter. The recombinant adenoviruses were propagated with 293 cells and the titers of the adenoviral preparations were determined by plaque-forming assay on 293 cells. Briefly, serial 10-fold dilutions of adenovirus were added to 24-well plates (Corning Glass Works, Corning, NY, USA), containing confluent 293 cell monolayers. After 48 h of incubation in a humidified atmosGene Therapy phere, the end point of 50% infectivity was determined according to the cytopathic effect. The recombinant adenoviruses produced were adjusted to a titer of 10 10 p.f.u./ml in PBS and stored at −70°C.
Preparation of murine peritoneal macrophages
Resident macrophages were washed from the peritoneal cavity with 5 ml RPMI-1640. After centrifugation at 110 g for 10 min at 4°C, the cell pellet was resuspended in complete media and adherent macrophages were obtained by plating the cells into 24-well or 96-well plastic trays (Corning Glass Works). 32 The nonadherent cells were rinsed off by vigorously washing with RPMI-1640 and the adherent cells were collected by gentle scraping with rubber policemen and determined by FACScan (Becton Dickinson, San Jose, CA, USA) with specific monoclonal antibody F4/80 (PharMingen, San Diego, CA, USA), and the 95% of the collected macrophages were found to express F4/80 marker (data not shown).
Gene transfer and pulsing of macrophages
The macrophages were incubated with recombinant virus AdM-CSF or AdIFN␥ at a multiplicity of infection (MOI) of 100:1 for 2 h at 37°C with constant agitation in a minimum volume of medium (500 l) to permit efficient infection. The macrophages were also infected with AdLacZ at MOI of 100:1 and 95% of the cells were efficiently transduced with recombinant adenoviruses when assayed by X-gal staining (data not shown). After incubation, 1 × 10 6 macrophages were washed twice in complete media to remove free viral particles, and then resuspended in fresh RPMI-1640 medium containing 5% FCS. The supernatants were collected for the assay of human M-CSF and murine IFN␥ contents by ELISA (Endogen, Cambridge, MA, USA).
For pulsing of macrophages, tumor lysates were prepared by three cycles of freezing/thawing B16F10 melanoma cells (1 × 10 7 /ml). Gene-modified macrophages were incubated with the tumor lysates (macrophages: melanoma cells, 5:1) for 4 h and then the cells were washed three times before injection.
Antigen presentation by the gene-modified macrophages C57BL/6 mice were immunized with 0.2 ml of 1 mg/ml chicken egg albumin (OVA, Sigma) twice with an interval of 7 days and spleen cells were isolated from dead mice 7 days after second immunization. T cells were separated as reported elsewhere. 5 The macrophages isolated from naive mice were infected with AdM-CSF or/and AdIFN␥ gene for 24 h then incubated with 1 mg/ml OVA for 2 h. OVA-pulsed, gene-modified macrophages (1 × 10 6 /ml) and T cells (4 × 10 6 /ml) were co-incubated for 24 h to induce IL-2 production.
Phenotype analysis of gene-modified macrophages
The gene-modified macrophages were washed with PBS three times and incubated with rat anti-mouse monoclonal antibodies against Ia, B7.1 and ICAM-1 (PharMingen) for 30 min at 4°C followed by PBS washing three times. Then the cells were incubated with FITC-conjugated goat anti-rat IgG (PharMingen) for 30 min at 4°C. The cells were then washed with PBS and resuspended in PBS containing 1% formaldehyde. Control incubations used for determining levels of background staining with the second antibody were irrelevant normal rat antimouse IgG. Flow cytometry were analyzed on a flow cytometer (Becton Dickinson FACScalibur).
Assay for cytotoxicity of peritoneal macrophages For macrophage cytotoxicity assay, macrophages were incubated with L1210 cells at E/T of 10 in a total volume of 0.1 ml medium per well in 96-well flat-bottomed plate. 33 After 20 h of co-incubation at 37°C, 5% CO 2 and 90% relative humidity, 20 l 5 mg/ml MTT (Sigma) was added to L1210 cells removed from macrophages. The plates were cultured for 4 h followed by the addition of 100 l 10% SDS in 0. 01 N HCl. The formazan crystals were dissolved in 10% SDS and the absorbance was read at 540 nm on a BioRad model 2550 microplate reader. Percentage of cytotoxicity was calculated relative to the calibration standard L1210 as follows: percentage of cytotoxicity = 1 − A L1210 remained /A L1210 standard .
IL-1 bioassay
The IL-1 activity was determined using proliferation of thymocytes. 34 Murine thymocytes stimulated with Con A 2.5 g/ml were plated in the wells of a flat-bottomed 96-well plate and serial dilutions of conditioned supernatants or standard recombinant human IL-1␤ were added and the cultures were incubated in 5% CO 2 at 37°C for 36 h. Proliferation of thymocytes in the presence of IL-1 or supernatants was measured by MTT method. The contents of IL-1 were defined as standard recombinant human IL-1.
IL-2 bioassay IL-2 activity was determined utilizing IL-2-dependent CTLL-2 cells. 34 Briefly, 2 x 10 4 CTLL-2 cells in a volume of 50 l were plated in the wells of a flat-bottomed 96-well plate. 50 l of serial dilutions of the supernatants or recombinant IL-2 (200 U/ml; Genzyme, Cambridge, MA, USA) were added and cultivated in 5% CO 2 at 37°C for 36 h. The proliferation of cells was measured by MTT method. Biological activity was defined by comparison to the standard recombinant murine IL-2.
TNF bioassay TNF bioassay was performed utilizing L929 cells as targets. 33 Briefly, L929 cells at 2 × 10 4 /well were plated in a 96-well plate to form monolayer. Supernatant in twofold dilutions was added to the cell monolayer in combination with 1 g/ml actinomycin D. One day later the L929 cells remaining alive after TNF lysis were determined by staining with 0.5% crystal violet and the absorbance of the dye dissolved in extraction solution was read on a BioRad model 2550 microplate spectrophotometer (BioRad, Richmond, USA). The cytotoxic activity (in units/ml) was defined as the reciprocal of the dilution resulting 50% cytotoxicity determined by plotting the regression line of log dilution against absorbance.
CTL cytotoxicity assay Four-hour 51 Cr release assay was performed for CTL cytotoxicity determination. 35 Splenic lymphocytes were isolated from dead tumor-bearing mice. The lymphocytes were co-cultured with irradiated B16F10 cells (2.5 × 10 5 /ml) in the presence of recombinant IL-2 200 U/ml (Genzyme) for 7 days, and then collected as CTL effector cells. The CTL activity was determined by a standard 4- Assay for NO secretion from peritoneal macrophages Nitrite contents in macrophage supernatants stimulated with LPS were measured by a microplate assay method described elsewhere. 36 Briefly, 50 l aliquots were removed from conditioned medium and incubated with an equal volume of Griess reagent (1% sulfanilamide and 0.1% naphthylethylene diamine dihydrochloride in 2.5% H 3 PO 4 ) at room temperature for 10 min. The absorbance at 550 nm was determined in BioRad model 2550 microplate reader. Sodium nitrite was used as standard. 36 Treatment of tumor-bearing mice C57BL/6 mice given 1 × 10 5 B16F10 cells intravenously into the tail vein will develop obvious melanoma metastasis on the lung. Twelve groups of mice with six mice in each group were used in each experiment. Each group received an intravenous injection of one of the following preparations: control RPMI-1640 medium, macrophages alone, macrophages pulsed with tumor lysates, M-CSF gene-modified macrophages, tumor-lysate-pulsed and M-CSF gene-modified macrophages, IFN␥ gene-modified macrophages, tumor-lysate-pulsed and IFN␥ gene-modified macrophages, M-CSF and IFN␥ gene-modified macrophages tumor-lysate-pulsed and M-CSF and IFN␥ gene-modified macrophages. Injections of 10 6 macrophages in 0.1 ml medium were performed 3 days after the inoculation of B16F10 melanoma cells and a booster of the same injections were given after another 4 days.
Statistics
All experiments were run in triplicate and the results are means ± s.d. of triplicate determinations (or representative data from one or two independent experiments). Statistical analysis was performed using the Student's t test.
